pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·May 4·1 min read
save

New study shows AI tools in emergency rooms are being overhyped, experts caution

May 4, 2026·read at STAT ↗Negative

A recent analysis of artificial‑intelligence applications in emergency departments concluded that the technology’s impact is far more modest than many headlines suggest. The authors warned that expectations have outpaced the evidence of clinical benefit.

The report has quickly become a talking point, with some commentators and vendors portraying the findings as a setback for AI adoption. The article argues that this amplification distorts the study’s nuanced conclusions and could mislead investors and clinicians.

Beyond the AI discussion, the newsletter highlighted ongoing lawsuits alleging health‑insurer fraud and announced an upcoming Georgetown panel on health‑care vertical integration, underscoring the complex regulatory and financial landscape facing the industry.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: Pump the brakes on AI, buddy; and deposition deadlock”

read at STAT ↗
489 words · retrieved May 4
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
AXSOME
drugs
Obesity
topics
Obesity2ImmunologyMonoclonal Antibody

related stories

  • Sep 29STAT+: AstraZeneca invests $2 billion in Summit TherapeuticsSTAT
  • Sep 286 immunology targets to sustain a mammoth I&I marketBioSpace
  • Sep 222026 IPO blitz continues with 4 new biotech filingsBioSpace
  • Sep 21Novo struggles to appease restive investors with consumer plans, blockbuster ambitionsFierce Biotech
  • Sep 18China plans to transform biotech sector into $522B powerhouse by 2030BioSpace